MedTrace Logo

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07599813 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2026-05-20

No results posted yet for this study

Summary

This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

Conditions

  • Atopic Dermatitis
  • Atopic
  • Dermatitis
  • Dermatitis, Atopic
  • Dermatologic Disease
  • Eczema
  • Eczema Atopic Dermatitis
  • Eczema, Atopic

Interventions

DRUG

Camoteskimab

Drug Product

DRUG

Placebo

Inactive substance

Sponsors & Collaborators

  • Apollo Therapeutics Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-15
Primary Completion
2027-10-31
Completion
2028-04-30
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Canada
  • Czechia
  • Germany
  • Hungary
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07599813 on ClinicalTrials.gov